Pharmacokinetic Drug Interaction Between Raloxifene and Cholecalciferol in Healthy Volunteers.
cholecalciferol
drug-drug interaction
osteoporosis
pharmacokinetics
raloxifene
Journal
Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
12
08
2021
accepted:
07
12
2021
pubmed:
6
1
2022
medline:
30
4
2022
entrez:
5
1
2022
Statut:
ppublish
Résumé
Osteoporosis is a common skeletal disorder, often leading to fragility fracture. Combination therapy with raloxifene, a selective estrogen receptor modulator, and cholecalciferol (vitamin D
Identifiants
pubmed: 34984851
doi: 10.1002/cpdd.1062
pmc: PMC9305550
doi:
Substances chimiques
Cholecalciferol
1C6V77QF41
Raloxifene Hydrochloride
4F86W47BR6
Banques de données
ClinicalTrials.gov
['NCT02654093']
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-631Informations de copyright
© 2022 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):23-9
pubmed: 10428318
Nanomaterials (Basel). 2020 May 31;10(6):
pubmed: 32486508
Clin Pharmacol Drug Dev. 2021 Aug;10(8):850-858
pubmed: 34190419
Breast Cancer Res Treat. 2008 Sep;111(2):377-88
pubmed: 17952589
Drug Metab Dispos. 2018 Dec;46(12):1856-1866
pubmed: 30232176
Am J Manag Care. 2011 May;17 Suppl 6:S164-9
pubmed: 21761955
Transl Res. 2012 Oct;160(4):298-308
pubmed: 22683417
Drugs. 2000 Aug;60(2):379-411
pubmed: 10983739
Clin Ther. 2014 Jan 1;36(1):48-57
pubmed: 24378207
Clin Interv Aging. 2017 Jul 06;12:1065-1077
pubmed: 28740372
Br J Nutr. 2013 Feb 14;109(3):493-502
pubmed: 22583563
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15;961:62-70
pubmed: 24861873
P T. 2018 Feb;43(2):92-104
pubmed: 29386866
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Am Fam Physician. 1999 Sep 15;60(4):1131-9
pubmed: 10507743
QJM. 2005 Sep;98(9):667-76
pubmed: 16006498
Eur J Pediatr. 2012 Oct;171(10):1475-80
pubmed: 22562162
Nat Rev Endocrinol. 2017 Aug;13(8):466-479
pubmed: 28387318
Drug Metab Pharmacokinet. 2015 Dec;30(6):425-33
pubmed: 26611713
J Clin Endocrinol Metab. 2010 Dec;95(12):5443-8
pubmed: 20843951
J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17
pubmed: 12161484
J Pharmacol Exp Ther. 2009 Aug;330(2):389-402
pubmed: 19414624
Mol Neuropsychiatry. 2019 Mar;5(1):28-41
pubmed: 31019916
FASEB J. 2019 Feb;33(2):2084-2094
pubmed: 30222077
J Clin Pharmacol. 2011 Oct;51(10):1439-48
pubmed: 21148044
Pharm Res. 2015 Mar;32(3):1128-40
pubmed: 25319098
Treat Endocrinol. 2005;4(6):371-7; discussion 379
pubmed: 16318403
Am J Health Syst Pharm. 2000 Sep 15;57(18):1669-75; quiz 1676-8
pubmed: 11006795
J Transl Med. 2012 Apr 25;10:76
pubmed: 22533838
Trends Endocrinol Metab. 1999 Oct;10(8):317-319
pubmed: 10481162
J Korean Med Sci. 2014 Jan;29(1):149-52
pubmed: 24431921
Br J Clin Pharmacol. 2009 Apr;67(4):437-44
pubmed: 19371317